Zuckerman Investment Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Zuckerman Investment Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,000	Closed	-$171K	–	164
2025 Q3	$171K	Hold	35,000	–	–	0.02%	152
2025 Q2	$177K	Hold	35,000	–	–	0.02%	148
2025 Q1	$185K	Buy	35,000 +1,000	+3%	+$7.29K	0.02%	154
2024 Q4	$247K	Sell	34,000 -6,000	-15%	-$40.3K	0.02%	137
2024 Q3	$264K	Buy	40,000 +15,000	+60%	+$108K	0.03%	126
2024 Q2	$188K	Buy	+25,000	New	+$218K	0.02%	138

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Zuckerman Investment Group's RXRX Position: Q4 2025 in Review

Zuckerman Investment Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 35,000 shares — an estimated $171K sold.

Zuckerman Investment Group first reported a position in RXRX in Q2 2024 and held it in 6 quarters. The position peaked at $264K in Q3 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Zuckerman Investment Group reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Zuckerman Investment Group sold 35,000 Recursion Pharmaceuticals shares in Q4 2025, an estimated $171K.
Zuckerman Investment Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Zuckerman Investment Group's Recursion Pharmaceuticals position peaked at $264K in Q3 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Zuckerman Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.